Parchure 2002.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 40 adults and elderly (macrolide n = 20, placebo n = 20) Age in years (mean ± SD): macrolide: 56 ± 9, placebo: 54 ± 10 Setting: secondary care
Interventions	Indication: coronary artery disease and antibodies positive to Chlamydia pneumoniae Type of macrolide: azithromycin Route: per oral Dose per day: 500 mg for 3 days, then 500 mg once a week for an additional 4 weeks Duration of treatment: 5 weeks Total treatment dose: 3500 mg
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: no Adverse events ascertainment: unclear Adverse events: not reported Antimicrobial resistance: not reported Death: not reported
Funding sources	Supported by the British Heart Foundation
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not described.
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants and clinicians blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (reporting bias)	High risk	Adverse events not stated as an outcome, unclear ascertainment, and no reporting of adverse events.
Other bias	Low risk	None were identified.